Ibrahim Jalal - Hikma Pharmaceuticals Insider

HIK -- UK Stock  

GBp 1,480  1.50  0.10%

Sr. Corporate VP of Technical Affairs
Dr. Ibrahim Jalal is Senior Corporationrationrate Vice President Technical Affairs of Hikma Pharmaceuticals Plc. Ibrahim joined Hikma as Technical Director and has held a variety of roles including Corporationrationrate Technical Vice President for Compliance and Senior Corporationrationrate Vice President for RD. He has played a leading role in Hikma securing FDA approval for its manufacturing units. Ibrahim holds a PhD in Pharmacy from the University of WisconsinMadison.
  VP Since 2008  Ph.D    
44 20 7399 2760  http://www.hikma.com

Management Efficiency

The company has return on total asset (ROA) of 5.45 % which means that it generated profit of $5.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of (42.6) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 777 M in total debt with debt to equity ratio (D/E) of 50.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Hikma Pharmaceuticals PLC has Current Ratio of 1.94 which is within standard range for the sector.

Similar Executives

Found 1 records

VP Since

Andy BurrowsBTG plc

Entity Summary

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in UK and traded on London Stock Exchange. It employs 8500 people.Hikma Pharmaceuticals PLC (HIK) is traded on London Stock Exchange in UK. It is located in 1 New Burlington Place and employs 8,500 people.

Hikma Pharmaceuticals Leadership Team

Fadi Nassar, President
Bassam Kanaan, Executive, MBA
Khalid Nabilsi, CFO, MBA
Hussein Arkhagha, Executive
Susan Ringdal, President, MBA
Pamela Kirby, Director, Ph.D
John Castellani, Director
Brian Hoffman, President, MBA
Ali AlHusry, Director, MBA
Jochen Gann, Director
Peter Speirs, Executive
Patrick Butler, Director
Said Darwazah, Chairman, MBA
Michael Raya, CEO
Ronald Goode, Director, Ph.D
Bryan Hotston, Executive
Sigurdur Olafsson, CEO
Breffni Byrne, Director
Nina Henderson, Director
Ragheb AlShakhshir, President
Michael Ashton, Director, MBA
Majda Labadi, President
Ibrahim Jalal, VP, Ph.D
Riad Mishlawi, President
Robert Pickering, Director
Mazen Darwazah, Chairman

Stock Performance Indicators

Did you try this?

Run Portfolio Anywhere Now

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Portfolio Anywhere

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Cryptocurrency Correlation module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges.